During perioperative care for non-small cell lung cancer (NSCLC) patients, clinical outcomes vary significantly.
There is a critical need for more dependable biomarkers to identify high-risk individuals in the perioperative phase.
This is essential for enhancing postoperative interventions and positively influencing clinical results.
